Systemic delivery of genes to striated muscles using adeno-associated viral vectors
10.1038/nm1085
Crossref journal-article
Springer Science and Business Media LLC
Nature Medicine (297)
Bibliography

Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nature Medicine, 10(8), 828–834.

Authors 8
  1. Paul Gregorevic (first)
  2. Michael J Blankinship (additional)
  3. James M Allen (additional)
  4. Robert W Crawford (additional)
  5. Leonard Meuse (additional)
  6. Daniel G Miller (additional)
  7. David W Russell (additional)
  8. Jeffrey S Chamberlain (additional)
References 33 Referenced 534
  1. Hoshijima, M. et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8, 864–871 (2002). (10.1038/nm739) / Nat. Med. by M Hoshijima (2002)
  2. Musaro, A. et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 27, 195–200 (2001). (10.1038/84839) / Nat. Genet. by A Musaro (2001)
  3. Harper, S.Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253–261 (2002). (10.1038/nm0302-253) / Nat. Med. by SQ Harper (2002)
  4. Greelish, J.P. et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat. Med. 5, 439–443 (1999). (10.1038/7439) / Nat. Med. by JP Greelish (1999)
  5. Bridges, C.R. et al. Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation. Ann. Thorac. Surg. 73, 1939–1946 (2002). (10.1016/S0003-4975(02)03509-9) / Ann. Thorac. Surg. by CR Bridges (2002)
  6. Huard, J. et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2, 107–115 (1995). / Gene Ther. by J Huard (1995)
  7. Cho, W.K. et al. Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route. Hum. Gene Ther. 11, 701–714 (2000). (10.1089/10430340050015608) / Hum. Gene Ther. by WK Cho (2000)
  8. Zhang, G., Budker, V., Williams, P., Hanson, K. & Wolff, J.A. Surgical procedures for intravascular delivery of plasmid DNA to organs. Methods Enzymol. 346, 125–133 (2002). (10.1016/S0076-6879(02)46052-1) / Methods Enzymol. by G Zhang (2002)
  9. Dellorusso, C. et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. Natl. Acad. Sci. USA 99, 12979–12984 (2002). (10.1073/pnas.202300099) / Proc. Natl. Acad. Sci. USA by C Dellorusso (2002)
  10. Watchko, J. et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther. 13, 1451–1460 (2002). (10.1089/10430340260185085) / Hum. Gene Ther. by J Watchko (2002)
  11. Halbert, C.L., Rutledge, E.A., Allen, J.M., Russell, D.W. & Miller, A.D. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74, 1524–1532 (2000). (10.1128/JVI.74.3.1524-1532.2000) / J. Virol. by CL Halbert (2000)
  12. Scott, J.M. et al. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul. Disord. 12, S23–S29 (2002). (10.1016/S0960-8966(02)00078-0) / Neuromuscul. Disord. by JM Scott (2002)
  13. Roberts, W.G. & Palade, G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108, 2369–2379 (1995). (10.1242/jcs.108.6.2369) / J. Cell Sci. by WG Roberts (1995)
  14. Senger, D.R., Perruzzi, C.A., Feder, J. & Dvorak, H.F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46, 5629–5632 (1986). / Cancer Res. by DR Senger (1986)
  15. Hauser, M.A. et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol. Ther. 2, 16–25 (2000). (10.1006/mthe.2000.0089) / Mol. Ther. by MA Hauser (2000)
  16. Hartigan-O'Connor, D., Kirk, C.J., Crawford, R., Mule, J.J. & Chamberlain, J.S. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol. Ther. 4, 525–533 (2001). (10.1006/mthe.2001.0496) / Mol. Ther. by D Hartigan-O'Connor (2001)
  17. Grimm, D. et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102, 2412–2419 (2003). (10.1182/blood-2003-02-0495) / Blood by D Grimm (2003)
  18. Yuasa, K. et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther. 9, 1576–1588 (2002). (10.1038/sj.gt.3301829) / Gene Ther. by K Yuasa (2002)
  19. Pinson, K.I., Dunbar, L., Samuelson, L. & Gumucio, D.L. Targeted disruption of the mouse villin gene does not impair the morphogenesis of microvilli. Dev. Dyn. 211, 109–121 (1998). (10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7) / Dev. Dyn. by KI Pinson (1998)
  20. Petrof, B.J., Shrager, J.B., Stedman, H.H., Kelly, A.M. & Sweeney, H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA 90, 3710–3714 (1993). (10.1073/pnas.90.8.3710) / Proc. Natl. Acad. Sci. USA by BJ Petrof (1993)
  21. Gregorevic, P. & Chamberlain, J.S. Gene therapy for muscular dystrophy - a review of promising progress. Expert Opin. Biol. Ther. 3, 803–814 (2003). / Expert Opin. Biol. Ther. by P Gregorevic (2003)
  22. Sakamoto, M. et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem. Biophys. Res. Commun. 293, 1265–1272 (2002). (10.1016/S0006-291X(02)00362-5) / Biochem. Biophys. Res. Commun. by M Sakamoto (2002)
  23. Ahmad, A., Brinson, M., Hodges, B.L., Chamberlain, J.S. & Amalfitano, A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum. Mol. Genet. 9, 2507–2515 (2000). (10.1093/hmg/9.17.2507) / Hum. Mol. Genet. by A Ahmad (2000)
  24. Phelps, S.F. et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet. 4, 1251–1258 (1995). (10.1093/hmg/4.8.1251) / Hum. Mol. Genet. by SF Phelps (1995)
  25. Arruda, V.R. et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol. Ther. 4, 586–592 (2001). (10.1006/mthe.2001.0491) / Mol. Ther. by VR Arruda (2001)
  26. Herzog, R.W. et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum. Gene Ther. 13, 1281–1291 (2002). (10.1089/104303402760128513) / Hum. Gene Ther. by RW Herzog (2002)
  27. Manno, C.S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963–2972 (2003). (10.1182/blood-2002-10-3296) / Blood by CS Manno (2003)
  28. Eppler, S.M. et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther. 72, 20–32 (2002). (10.1067/mcp.2002.126179) / Clin. Pharmacol. Ther. by SM Eppler (2002)
  29. Herzog, R.W. et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5, 56–63 (1999). (10.1038/4743) / Nat. Med. by RW Herzog (1999)
  30. Rutledge, E.A., Halbert, C.L. & Russell, D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319 (1998). (10.1128/JVI.72.1.309-319.1998) / J. Virol. by EA Rutledge (1998)
  31. Grimm, D., Kern, A., Rittner, K. & Kleinschmidt, J.A. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther. 9, 2745–2760 (1998). (10.1089/hum.1998.9.18-2745) / Hum. Gene Ther. by D Grimm (1998)
  32. Halbert, C.L., Allen, J.M. & Miller, A.D. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J. Virol. 75, 6615–6624 (2001). (10.1128/JVI.75.14.6615-6624.2001) / J. Virol. by CL Halbert (2001)
  33. Rafael, J.A. et al. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J. Cell Biol. 134, 93–102 (1996). (10.1083/jcb.134.1.93) / J. Cell Biol. by JA Rafael (1996)
Dates
Type When
Created 21 years, 1 month ago (July 25, 2004, 1:27 p.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 6:02 p.m.)
Indexed 6 minutes ago (Sept. 3, 2025, 4:45 a.m.)
Issued 21 years, 1 month ago (July 25, 2004)
Published 21 years, 1 month ago (July 25, 2004)
Published Online 21 years, 1 month ago (July 25, 2004)
Published Print 21 years, 1 month ago (Aug. 1, 2004)
Funders 0

None

@article{Gregorevic_2004, title={Systemic delivery of genes to striated muscles using adeno-associated viral vectors}, volume={10}, ISSN={1546-170X}, url={http://dx.doi.org/10.1038/nm1085}, DOI={10.1038/nm1085}, number={8}, journal={Nature Medicine}, publisher={Springer Science and Business Media LLC}, author={Gregorevic, Paul and Blankinship, Michael J and Allen, James M and Crawford, Robert W and Meuse, Leonard and Miller, Daniel G and Russell, David W and Chamberlain, Jeffrey S}, year={2004}, month=jul, pages={828–834} }